Talk:Eribulin

This is the talk page for discussing improvements to the Eribulin article.
This is not a forum for general discussion of the subject of the article.

Add new text under old text.
New to Wikipedia? Welcome! Learn to edit; get help.

Start a new topic

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Eribulin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Does it have any approvals in Europe - or are any pending decision

Latest comment: 6 months ago2 comments2 people in discussion

- Rod57 (talk) 23:21, 30 January 2016 (UTC)Reply

This is a 10-year old question with no responses, so will respond here although by now Rod57 probably has his answer. Yes, eribulin is approved in the EU for locally advanced or metastatic breast cancer and advanced, unresectable liposarcoma. Please see actual EU approval indications for details of pre-treatment requirements, which are not included here. Macrocycle1 (talk) 23:54, 25 April 2026 (UTC)Reply